UR
UR8.F UroGen Pharma Ltd
- Market cap
- EUR 1.14B
- P/E
- -
- P/B
- 25.09x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is UR8.F undervalued?
Graham numberThe Graham number of UroGen Pharma Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
UroGen Pharma Ltd fundamental analysis
No fundamental analysis for UroGen Pharma Ltd yet.
UroGen Pharma Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment …
Full company profileUroGen Pharma Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
UroGen Pharma Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 17.5M | 8.16M | 1.13M | 18.0K | 11.8M | 48.0M | 64.4M | 82.7M | 90.4M | 110M | 283M |
| Gross Profit | 17.5M | 7.56M | -675K | 18.0K | 10.8M | 42.9M | 56.7M | 73.4M | 81.5M | 97.3M | 259M |
| Operating Income | 798K | -20.0M | -77.2M | -109M | -127M | -92.3M | -79.0M | -65.5M | -96.8M | -125M | -15.8M |
| EBITDA | - | -19.7M | -76.8M | -108M | -125M | -90.5M | -99.6M | -81.9M | -110M | -136M | -28.8M |
| Net Income | -1.94M | -20.0M | -75.7M | -105M | -128M | -111M | -109M | -102M | -127M | -153M | -52.5M |
| EPS | - | -1.45 | -4.67 | -5.00 | -5.80 | -4.93 | -4.72 | -3.15 | -3.00 | -3.17 | -1.07 |
| Balance Sheet | |||||||||||
| Total Assets | 23.1M | 75.6M | 104M | 202M | 122M | 120M | 136M | 178M | 286M | 200M | 272M |
| Total Liabilities | 6.75M | 7.04M | 13.5M | 22.1M | 25.7M | 111M | 225M | 244M | 295M | 306M | 397M |
| Shareholders' Equity | 16.3M | 68.5M | 90.1M | 180M | 96.4M | 8.41M | -89.4M | -65.2M | -8.80M | -105M | -125M |
| Cash & Short-term Investments | 21.4M | 37.0M | 101M | 49.7M | 52.9M | 44.4M | 55.4M | 95.0M | 172M | 111M | 85.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 4.19M | -9.57M | -37.3M | -71.0M | -106M | -84.9M | -87.6M | -76.4M | -96.8M | -162M | -125M |
| Capital Expenditure | 695K | 271K | 560K | 325K | 1.22M | 752K | 254K | 194K | 295K | 289K | 248K |
| Free Cash Flow | - | -9.84M | -37.9M | -71.3M | -107M | -85.6M | -87.8M | -76.6M | -97.1M | -163M | -125M |
| Ratios | |||||||||||
| ROE | -11.9% | -29.2% | -84.0% | -58.3% | -133.3% | -1,317.2% | - | - | - | - | - |
| ROA | -8.4% | -26.5% | -73.1% | -52.0% | -105.3% | -92.5% | -80.5% | -57.3% | -44.4% | -76.6% | -19.3% |
| Net Profit Margin | -11.1% | -245.2% | -6,707.2% | -584,144.4% | -1,088.9% | -230.7% | -169.6% | -123.6% | -140.4% | -139.8% | -18.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
UroGen Pharma Ltd dividends
UroGen Pharma Ltd has not paid dividends in the last 9 fiscal years.
Who owns UroGen Pharma Ltd
- Insiders 3.48%
- Institutions 96.52%
- Public & others 0.00%
- Shares outstanding 49.0M
- Free float 43.6M
UroGen Pharma Ltd company profile
- Company name
- UroGen Pharma Ltd
- Ticker
- UR8.F
- ISIN
- IL0011407140
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 300
- Fiscal year end
- December
- Address
- 400 Alexander Park Drive, Princeton, NJ, United States, 08540
- Phone
- 646 768 9780
- Website
- urogen.com
About UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
UroGen Pharma Ltd management
10- Ms. Elizabeth A. BarrettPresident, CEO & Director · born 1962
- Mr. Jason Drew Smith J.D.General Counsel, Chief Compliance Officer & Corporate Secretary · born 1972
- Dr. Mark P. Schoenberg M.D.Chief Medical Officer · born 1958
- Mr. Christopher Degnan CPAChief Financial Officer · born 1980
- Mr. Vincent I. PerroneSenior Director of Investor Relations
- Ms. Alison HardgroveSenior Vice President of Human Resources
- Dr. Marina Konorty Ph.D.Executive Vice President of Research & Development and Technical Operations
- Mr. James Ottinger R.ph.Executive Vice President of Regulatory Affairs & Quality
- Mr. Michael J. Louie M.D., M.P.H., M.Sc.Chief Development Officer
- Mr. Timothy SimonSenior Vice President of Business Development & Portfolio Strategy